A recent study evaluated the impact of adding bevacizumab to chemotherapy treatment for patients who were newly diagnosed with ovarian cancer. The results, published in Gynecologic Oncology, found that while the addition of bevacizumab greatly improved progression-free survival (PFS), it did not improve overall survival.
A recent study evaluated the impact of adding bevacizumab to chemotherapy treatment for patients who were newly diagnosed with ovarian cancer. The results, published in Gynecologic Oncology, found that while the addition of bevacizumab greatly improved progression-free survival (PFS), it did not improve overall survival (OS).
The open-label randomized phase 3 ICON7 trial enrolled women with newly diagnosed ovarian cancer that was either high-risk early stage or advanced. Patients were randomized after primary surgery (unless disease was inoperable) to receive 6 cycles of chemotherapy either alone or in combination with bevacizumab at 7.5 mg/kg every 3 weeks for up to 12 months until disease progression or unacceptable toxicity. The primary end point of the trial was PFS and the secondary end point was OS.
In total, the trial enrolled 119 patients with stage I disease, 163 patients with stage II disease, 1034 patients with stage III disease, and 201 patients with stage IV disease. The median duration of follow up was 28 months for PFS and 49 months for OS.
For PFS, the researchers found that all stages indicate better outcomes with the addition of bevacizumab. However, researchers noted that the data found for OS was less clear. This could be due to “the extremely low event rates in the stage I and stage II subgroups compared with the stage III and stage IV.”
Additionally, PFS and OS were also analyzed within the stage IIIB to IV subgroup. The study authors found that, irrespective of residual disease status, all patients in this subgroup derived a PFS benefit from the addition of bevacizumab to chemotherapy. Conversely, no OS difference was seen in either the stage IIIB to IV subgroup or the other subgroups classified by the presence or absence of residual disease.
Overall, the addition of bevacizumab to carboplatin and paclitaxel chemotherapy improved PFS in most of the evaluated subgroups. The study found that the main patient populations who appeared not to derive a PFS improvement from the addition of bevacizumab were those with stage I or II disease, though the authors note that this could be due to smaller sample sizes.
Reference
Martin A, Oza A, Embleton A, et al. Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer [published online November 15, 2018]. Gyn Oncol. doi: 10.1016/j.ygyno.2018.08.036.
Eye on Pharma: Henlius, Organon Updates; Meitheal Portfolio Expansion; Celltrion Zymfentra Data
November 5th 2024Henlius and Organon’s pertuzumab biosimilar met phase 3 goals; Meitheal expanded its US biosimilars; Celltrion’s subcutaneous infliximab (Zymfentra) showed monotherapy could be as effective as combination therapy for inflammatory bowel disease.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Panelists Stress Stakeholder Education to Build Confidence in Biosimilars
October 31st 2024By expanding educational initiatives to clarify biosimilar safety, efficacy, and interchangeability, stakeholders can foster trust, improve access, and ensure that biosimilars are widely accepted as high-quality, cost-effective alternatives to originator biologics.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Samsung Bioepis Report Showcases Adalimumab Biosimilar Growth in Market Share
October 11th 2024Adalimumab biosimilars have seen a significant increase in market share, from 2% in early 2024 to 22%, as payers and pharmacy benefit managers begin to prioritize these biosimilars over the reference product, Humira.